TASER International, Inc. (TASR) Stuns Bears with Big Rally

TASER International, Inc. (TASR) bears got a jolt this morning, but the struggling stock still has more ground to cover

by Elizabeth Harrow

Published on Nov 24, 2015 at 10:25 AM

It's been a rough year on the charts for TASER International, Inc. (NASDAQ:TASR). Through Monday's close, the stock was down more than 31% in 2015, woefully underperforming the broader equities market.

As a result, bears have flocked to the stun-gun stock. Short interest accounts for more than 25% of TASR's float, representing 7.1 times the equity's average daily trading volume.

Likewise, options players have been leaning toward bearish bets. The stock's 50-day put/call volume ratio on the International Securities Exchange (ISE), Chicago Board Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX) arrives in the 97th percentile of its annual range, marking a near-peak of pessimistically-skewed speculation on TASR.

While the stock's grim price action is certainly deserving of this heavy-handed skepticism, TASR is catching a boost today, as some of the weaker bearish hands stampede for the exits. The company announced that it's negotiating the final details of a contract to outfit the London Metropolitan Police Service with its Axon body-worn cameras, sending TASR shares up 4.6% this morning to trade at $19.08. The possibility of this deal going through also earned the stock an upgraded analyst rating last week.

The stock's short-squeeze rally could soon run out of steam, though, as TASR peaked today just shy of the round $20 level -- which is also the site of its descending 20-day moving average. Unless TASER International, Inc. (NASDAQ:TASR) can break out above multiple layers of resistance, the majority of the stock's skeptics are likely to remain firmly entrenched for now.

A Schaeffer's exclusive!

The Expert's Guide

Access your FREE trading earning announcements before it's too late!



NEW! Explore Schaeffer’s Partners' deals and get connected to top online brokerages with deals tailored exclusively for our readers.  Get answers to your questions regarding transfer fees, commission rates, programs and available discounts related to online trading services.

MORE | MARKETstories

The Latest Investor's Guide to Precious Metals
Learn how to protect savings and maximize returns by investing in precious metals.
Patent Lawsuit Loss Sends AMRN Stock Spiraling
Amarin just lost a major U.S. patent lawsuit for its heart drug Vascepa
RH Stock Sinks Despite Earnings Beat
J.P. Morgan Securities and Cowen and Company cut their price targets
The Latest Investor's Guide to Precious Metals
Learn how to protect savings and maximize returns by investing in precious metals.